VC pair seeds cancer play Yukin, seeks preclinical readout

Advent and Medicxi want to see a differentiated program for French newco Yukin’s kinase inhibitors targeting the NIK protein

While Advent France Biotechnology and Medicxi are taking a wait-and-see approach with Yukin's kinase inhibitors targeting the NIK protein for cancer, the firms believe they could follow the biotech's €3.3 million ($3.7 million) seed round with a larger series A round within a year.

Co-founded last

Read the full 453 word article

How to gain access

Continue reading with a
two-week free trial.